"Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.
Patients with LAL deficiency (also known as Wolman disea"...
(hydroxyamphetamine Hydrobromide 1% and tropicamide 0.25%)
Convenient One-Drop Solution for Dilation
- Convenient one-drop formulation is easier to administer than many current regimens consisting of a drop from two separate products.
For Patient and Practitioner Convenience
- Formulated to work quickly to fit busy patients' schedules and your patient flow.
- Only partial loss of accommodation, due to lower (0.25%) concentration of tropicamide.
- Minimizes inconvenience: Recovery begins within 90 minutes, with complete recovery typically in 6 to 8 hours.
PAREMYD® (hydroxyamphetamine hydrobromide, tropicamide) Solution should not be used in patients with angle-closure glaucoma or in those with narrow angles in whom dilation of the pupil may precipitate an attack of angle-closure glaucoma. This product is also contraindicated in patients who are hypersensitive to any of its components.
Additional Paremyd Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.